Cardiff Oncology to Present at B. Riley Securities' 3rd Annual Oncology Conference

Rhea-AI Summary

Cardiff Oncology (Nasdaq: CRDF) will participate in a fireside chat at B. Riley Securities' 3rd Annual Oncology Conference, scheduled for January 18-19, 2023. The chat will take place on January 18 at 1:30 PM ET. Investors can register for the live webcast through the provided link. Cardiff Oncology is focused on developing therapies leveraging PLK1 inhibition to treat various cancers, including KRAS/NRAS-mutated metastatic colorectal cancer and metastatic pancreatic ductal adenocarcinoma. For more details, visit their official website.

SAN DIEGO, Jan. 10, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat at B. Riley Securities' 3^rd Annual Oncology Conference, which is taking place virtually from January 18 – 19, 2023.

Details of the fireside chat can be found below.

B. Riley Securities' 3rd Annual Oncology Conference
Date:	January 18, 2023
Time:	1:30 PM ET
Registration Link:	Here

Those interested in viewing a live webcast of the fireside chat may register using the link above to gain access through the conference portal. A replay of the fireside chat will be available at the same location and archived for one year.

About Cardiff Oncology, Inc.

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor we are evaluating in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as KRAS/NRAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in triple negative breast cancer (TNBC) and small cell lung cancer (SCLC). These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.

Cardiff Oncology Contact:

James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com  

Investor Contact:

Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-to-present-at-b-riley-securities-3rd-annual-oncology-conference-301717462.html

SOURCE Cardiff Oncology, Inc.

FAQ

What is the date and time of Cardiff Oncology's presentation at B. Riley Securities' conference?

Cardiff Oncology will present on January 18, 2023, at 1:30 PM ET.

How can I register to watch Cardiff Oncology's fireside chat?

You can register for the webcast of Cardiff Oncology's fireside chat through the registration link provided in the press release.

What type of therapies is Cardiff Oncology developing?

Cardiff Oncology is developing therapies that leverage PLK1 inhibition to target various cancers.

What is the location of B. Riley Securities' 3rd Annual Oncology Conference?

The conference will be held virtually from January 18 to 19, 2023.

What is the main focus of Cardiff Oncology's research?

The main focus of Cardiff Oncology's research is on developing novel therapies for cancers like metastatic colorectal cancer and pancreatic cancer.